Induction Chemotherapy and Immunotherapy Combined Radiotherapy With or Without Concurrent Chemotherapy for Stage III-IVa NPC - Trial NCT06095167
Access comprehensive clinical trial information for NCT06095167 through Pure Global AI's free database. This Phase 3 trial is sponsored by Fujian Cancer Hospital and is currently Not yet recruiting. The study focuses on Nasopharyngeal Carcinoma. Target enrollment is 476 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Fujian Cancer Hospital
Timeline & Enrollment
Phase 3
Jan 01, 2024
Jan 01, 2028
Primary Outcome
Failure-free survival
Summary
The purpose of this study is to compare induction chemotherapy (gemcitabine+cisplatin) plus
 immunotherapy with concurrent chemoradiotherapy (CCRT) or RT alone in patients with stage
 III-IVa nasopharyngeal carcinoma(NPC), in order to confirm the value of Immunotherapy and
 concurrent chemotherapy in NPC patients.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06095167
Non-Device Trial